Finally, in a recent small, open-label randomized control trial, treatment with ezetimibe for 6 months improved hepatic fibrosis but increased hemoglobin A1c levels (40). In summary, although existing data showing that cholesterol-lowering drugs benefit NAFLD pathology and disease progression are ...